Clincosm LogoSign in Get a demo

RESET-YOUTH: Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects

Sponsor
Chandra Duggirala (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT03353597
Collaborator
(none)
2,120
Enrollment
1
Location
1
Arm
55
Anticipated Duration (Months)
38.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This trial is designed to study the effects of monthly transfusions of young healthy male donor plasma on biological age as assessed by DNA methylation levels, and changes in cognitive, renal, and pulmonary function, muscle strength, telomere length, testosterone, estrogen, DHEAS, IGF-1, high resolution C-Reactive protein, and expression of P16INK4a in peripheral blood T lymphocytes and skin biopsies.

Condition or Disease Intervention/Treatment Phase
  • Biological: Plasma Transfusion
 Phase 1/Phase 2

Detailed Description

Aging is a process for which there is no cure. Plasma transfusions, based on extensive animal studies, have the potential to reverse many, systemic age-related changes in the human body as well as age related chronic diseases. This is a non-randomized, uncontrolled phase I/II study to study the effects of monthly transfusions of young healthy male donor plasma on biological age as assessed by DNA methylation levels, and changes in cognitive, renal, and pulmonary function, muscle strength, telomere length, testosterone, estrogen, DHEAS, IGF-1, high resolution C-Reactive protein, and expression of p16INK4a in peripheral blood T lymphocytes and skin biopsies. To determine the safety and tolerability of monthly, 2-unit transfusions of young (<25 years of age) healthy male donor plasma for 6 months in patients older then 40 years of age.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2120 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects
Anticipated Study Start Date :
May 15, 2018
Anticipated Primary Completion Date :
Jun 15, 2020
Anticipated Study Completion Date :
Dec 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Plasma Transfusion

Plasma Transfusions with 2 units of plasma per dose, for a total of 6 doses

Biological: Plasma Transfusion
All subjects will receive monthly, 2-unit transfusions of young healthy male donor plasma for total of 6 treatments. The plasma will be administered at a transfusion services facility in a manner consistent with generally accepted and standard guidelines for plasma transfusions.

Outcome Measures

Primary Outcome Measures

  1. Biological age as assessed by DNA methylation levels, to calculate the Epigenetic age. [Baseline to end of Month 9.]

    The "epigenetic clock," as assessed by DNA methylation levels, which has been shown to be highly correlated with biologic age, longevity and is an independent predictor of mortality.

Secondary Outcome Measures

  1. Mental (Cognitive) Function [Baseline and Month 9]

    Executive functioning, as measured by the California Stroop test

  2. Lung (Pulmonary) Function [Baseline and Month 9]

    FEV1 (Forced Expiratory Volume during the first second), and Peak Expiratory Flow

  3. Kidney (Renal) Function [Baseline and Month 9]

    Twenty-four hour urine collections will be performed by patients at Baseline and at Month 9. Creatinine Clearance, a measure of Renal function will be determined by calculating the glomerular filtration rate (GFR), which is the sum of filtration rates in all functioning nephrons.

  4. Muscle Strength [Baseline and Month 9]

    Unilateral Maximal Voluntary Isometric and Concentric Strength

  5. Telomere Length [Baseline and Month 9]

    A telomere is a region of repetitive nucleotide sequences at each end of a chromosome, which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes. Telomere shortening is associated with aging, mortality and aging-related diseases. Average telomere length will be measured in white blood cells by real time PCR technique.

  6. Testosterone [Baseline and Month 9]

    Serum free and total Testosterone levels

  7. Estrogen [Baseline and Month 9]

    Serum Estrogen levels

  8. DHEAS [Baseline and Month 9]

    Dehydroepiandrosterone is an endogenous steroid hormone that has a role in the synthesis of sex steroids (androgens and estrogens), as well as neurotrophic and other effects

  9. IGF-1 [Baseline and Month 9]

    Insulin Like Growth Factor -1(IGF-1) declines continuously with aging in adults, and has been shown to mediate a number of pathways that are associated with longevity.

  10. High Sensitivity C-Reactive Protein [Baseline and Month 9]

    C-Reactive Protein is a blood protein that is a marker of inflammation. Studies have suggested that a persistent level of inflammation plays a major role in cardiovascular and other degenerative and aging related diseases.

  11. P16INK4a (A marker of cellular aging) [Baseline and Month 9]

    The cyclin- dependent kinase inhibitor CDKN2A, commonly referred to as p16INK4a or p16, has been established as a general marker of cellular senescence or aging. The expression of p16INK4a has been shown to increase exponentially with chronologic age. P16-INK4a is performed on a small specimen of blood drawn from the subjects, as well as from skin biopsy samples.

Other Outcome Measures

  1. Exploratory biomarkers [Baseline,1,2,3,4,5,6, and 9 months.]

    Blood, and urine, proteomic signatures of aging, including Interleukin-6, Tumor Necrosis Factor Alpha, Tissue Inhibitor of Metallo Proteinases-2, Transforming Growth Factor-Beta, and Mechanistic Target of Rapamycin (mTOR) levels, that are associated with various cellular, genetic and physiological mechanisms of aging will be measured at Baseline, 1,2,3,4,5,6, and 9 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Age > 40.

  • Stable medications for 2 months prior to Screening.

  • Signed and dated written informed consent obtained from the subject in accordance with local Institutional Review Board regulations.

  • Males and all Women of Child Bearing Potential agree to abstain from sex or use an adequate method of contraception for the duration of the study and for 30 days after the last dose of study drug. Adequate contraceptive methods include those with a low failure rate, i.e., less than 1% per year, when used consistently and correctly), and , a woman who has been surgically sterilized or who has been in a state of amenorrhea.

Exclusion Criteria:

  • Dementia of any etiology.

  • Any medical condition other than dementia that could account for cognitive deficits (e.g., active seizure disorder, stroke, Central Nervous System diseases);

  • History of significant cardiovascular, hematologic, renal, or advanced hepatic disease (or laboratory evidence thereof);

  • History of major psychiatric illness or untreated depression;

  • Neutrophil count <1,500/mm3, platelets <100,000/mm3, serum creatinine >1.5x upper limit of normal (ULN), total bilirubin >1.5 x ULN, Alanine Transaminase >3 x ULN, Aspartate Transaminase >3 x ULN, or International Normalized Ratio (INR) >1.2 at Screening evaluations;

  • Evidence of any clinically significant findings on Screening or baseline evaluations which, in the opinion of the Investigator would pose a safety risk or interfere with appropriate interpretation of study data;

  • Current or recent history (within four weeks prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection;

  • Current clinically significant viral infection;

  • Major surgery within four weeks prior to Screening;

  • Any contraindication to monthly plasma transfusions, including but not limited to:

  • History of significant transfusion complications;

  • Compatible plasma units not available;

  • Prior intolerance to intravenous (IV) fluids;

  • Immunoglobulin A deficiency by history or laboratory evidence at Screening;

  • Bleeding;

  • Any concurrent use of an anti-coagulant therapy.

  • Daily administration of Aspirin 81mg will be allowed as long as the dose is stable for 30 days prior to Screening. Anti-platelet drugs are acceptable.

  • Treatment with another investigational drug or participation in another interventional clinical trial within 3 months of Screening;

  • Treatment with any human blood product, including IV immunoglobulin, during the 6 months prior to Screening or during the trial;

  • Pregnant or lactating;

  • Positive pregnancy test at Screening or Baseline (Day 1);

  • Cancer within 5 years of Screening, except for nonmetastatic skin cancer or non-metastatic prostate cancer not expected to cause significant morbidity or mortality within one year of Baseline.

  • AB blood type.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Infusion Center & Clinic San Mateo California United States 94401

Sponsors and Collaborators

  • Chandra Duggirala

Investigators

  • Principal Investigator: Chandra s duggirala, Fountain Labs, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Chandra Duggirala, Principal Investigator, Fountain Labs, Inc.
ClinicalTrials.gov Identifier:
NCT03353597
Other Study ID Numbers:
  • FFP-1
First Posted:
Nov 27, 2017
Last Update Posted:
Jan 17, 2018
Last Verified:
Jan 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Jan 17, 2018